Skip to main content

Pathogenic peptides to enhance treatment of glioblastoma: evaluation of RVG-29 from rabies virus and chlorotoxin from scorpion venom

Abstract Glioblastoma (GBM) is a highly invasive and deadly late stage tumor that develops from abnormal astrocytes in the brain. With few improvements in treatment over many decades, median patient survival is only 15 months and the 5-year survival rate hovers at 6%. Numerous challenges are encountered in the development of treatments for GBM. The blood-brain barrier (BBB) serves as a primary obstacle due to its innate ability to prevent unwanted molecules, such as most chemotherapeutics, from entering the brain tissue and reaching malignant cells. The GBM cells themselves serve as a second obstacle, having a high level of genetic and phenotypic heterogeneity. This characteristic improves the probability of a population of cells to have resistance ... (more)
Created Date 2019
Contributor Cook, Rebecca Leanne (Author) / Blattman, Joseph N (Advisor) / Sirianni, Rachael W (Advisor) / Mor, Tsafrir (Committee member) / Anderson, Karen (Committee member) / Arizona State University (Publisher)
Subject Oncology / Immunology / Nanotechnology / Brain tumors / Chlorotoxin / Drug delivery / Glioblastoma / Immunotherapy / Protein engineering
Type Doctoral Dissertation
Extent 148 pages
Language English
Note Doctoral Dissertation Biological Design 2019
Collaborating Institutions Graduate College / ASU Library
Additional Formats MODS / OAI Dublin Core / RIS

This content is under embargo until Aug 01, 2021

  Full Text
2.4 MB application/pdf
  • Download restricted
Download Count: 0

Description Dissertation/Thesis